ELSEVIER

European Journal of Cancer 41 (2005) 2704–2708

European Journal of Cancer

www.ejconline.com

Combined Pap and HPV testing in primary screening for cervical abnormalities: Should HPV detection be delayed until age 35?

Marc F.D. Baay [a,*], Wiebren A.A. Tjalma [b], Hilde A.J. Lambrechts [a], Greet G.O. Pattyn [a], Filip Lardon [a], Joost Weyler [c], Paul Van Royen [d], Eric A.E. Van Marck [e], Jan B. Vermorken [a]

[a] *Department of Medical Oncology, University of Antwerp (CDE, T3), Universiteitsplein 1, 2610 Wilrijk, Belgium*
[b] *Department of Gynaecology and Gynaecological Oncology, University of Antwerp (UA/UZA), Edegem, Belgium*
[c] *Department of Epidemiology and Community Medicine, University of Antwerp, Wilrijk, Belgium*
[d] *Centre for General Practice, University of Antwerp, Wilrijk, Belgium*
[e] *Department of Pathology, University of Antwerp (UA/UZA), Edegem, Belgium*

Received 20 January 2005; received in revised form 29 March 2005; accepted 12 April 2005
Available online 18 October 2005

Abstract

In 2003, the United States Food and Drug Administration has approved the Hybrid Capture 2 assay for use with a Pap test to adjunctively screen women of 30 years and older for the presence of high-risk human papillomavirus (HR-HPV) infection. Although the predictive power of a negative test is strong, the number of false-positives may still be high. We investigated HPV prevalence in relation to age in a group of 2293 women, aged between 20 and 50, with normal cytology. Overall HR-HPV prevalence was 6.9% (95%CI = 5.9–8.0%). Regression analysis using 5-year intervals showed that the HR-HPV prevalence did not significantly decline up to age 34, whereas it declined significantly after age 35. This would suggest that postponing HPV detection in primary screening from age 30 to 35 would result in a decrease of almost 50% of the number of women with normal cytology and a transient HPV infection. However, larger scale studies are required to confirm this finding.

Keywords: Cervical cancer; Human papillomavirus; Primary screening

1. Introduction

The age-related prevalence of both high-risk and low-risk human papillomavirus (HPV) types in cytologically normal cervical smears has been shown by a number of studies [1–6]. Based upon these data and because of the frequency of asymptomatic HPV infections, as well as transient low-grade cervical lesions it has been suggested that HPV testing within primary cervical cancer screening would be unwise before the age of 30 years [7]. In 2003, the United States Food and Drug Administration (FDA) has approved Digene's Hybrid Capture 2 (HC2) assay for use with a Pap test to adjunctively screen women of 30 years and older for the presence of high-risk (HR) HPV infection, based on the theory that after the age of 30, the negative predictive value of both Pap and HC2 would improve the sensitivity of cervical cancer screening. Although the predictive power of a negative test is high, the number of HPV positive women may still be substantial. A fraction of these women will have a persistent infection and may go on to develop cervical lesions. Alternatively, a fraction of these women may have cervical lesions already, which were missed by cytology. However, a very large majority of HPV positive women, especially in younger age groups, will have

* Corresponding author. Tel.: +3238202576; fax: +3238202248.
E-mail address: Marc.Baay@ua.ac.be (M.F.D. Baay).

0959-8049/$ - see front matter © 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejca.2005.04.050

a transient infection which will not cause progressive lesions, and may, therefore, be considered as false-positive. It has been shown previously that the median duration of HPV infection is between 8 and 12 months [8–10]. Furthermore, 10 months after incident infection, 50% of the women were no longer infected [10]. This number increased to 70% at 12 months, 91% at 24 months and 92% at 5 years [8,11].

In this study, we investigated HPV prevalence in relation to age in a group of 2293 women, aged between 20 and 50, with normal cytology.

2. Patients and methods

2.1. Study group

Between January 2001 and June 2003 cytology material from women attending the Department of Gynaecology at the University Hospital Antwerp for regular cervical cancer screening and women attending their general practitioner was included in this study. The study was performed anonymously; the only data available were age at sampling and result of cytology. Only women with normal cytology ($n = 2318$) were included in the analysis. The mean age of these women was 35.8 years. The study protocol was approved by the medical ethical board of Antwerp University.

2.2. Sample preparation and HPV detection

The residual material after preparation of thin layer cytology slides was used for HPV detection. The suspension was centrifuged for 5 min at 1207 g. Cells were resuspended in 0.5 ml TE (10 mM Tris–HCl pH 8.0, 1 mM EDTA) and frozen at −80 °C. After thawing, 100 μl of the suspension was taken, boiled for 10 min and centrifuged (5 min, 12,557 g). Isolation of DNA was checked by β-globin PCR [12]. Only from β-globin positive samples, 10 μl of the suspension was subjected to the GP5+/6+ HPV PCR [13]. Detection of PCR products was performed in an enzyme immunoassay format as described by Jacobs *et al.* [14]. Presence of HPV was detected with a high-risk (HR) HPV probe cocktail. The cut-off value for HPV positivity was calculated as the mean plus three times the standard deviation of six negative controls in each plate (DNA isolated from cell line A549, an HPV negative lung cancer cell line). Typing analysis on HPV positive samples was performed in an enzyme immunoassay with separate probes for HR HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.

2.3. Statistical analysis

Logistic regression for HPV prevalence in different age groups was performed with age as a continuous variable and with 5- and 10-year intervals as categoric variables.

3. Results

Cervical smear material was obtained from 2318 women with normal cytology. Material from 25 samples (1.1%) was negative on β-globin PCR, and these were excluded from the analyses. Overall HR-HPV prevalence in this study was 6.9% (158 of 2293 women, 95%CI = 5.9–8.0%). The age-related HR-HPV prevalence was analysed in 10-year intervals (Table 1, Fig. 1), in 5-year intervals (Table 1, Fig. 2) and in intervals of 1 year (data not shown). Using 5-year intervals the HPV prevalence remained stable at approximately 9% in the age groups 20–24, 25–29 and 30–34, and decreased significantly to approximately 5% in the age

Table 1
Age-specific HPV prevalence in women with normal cytology

Age group	*N*	HPV+	% HPV+	95%CI	*P*-value[a]
20–29	710	64	9.0	7.0–11.4	Ref.
30–39	772	55	7.1	5.4–9.2	0.182
40–50	811	39	4.8	3.4–6.5	0.001
20–24	314	28	8.9	6.0–12.1	Ref.
25–29	396	36	9.1	6.5–12.4	0.936
30–34	411	38	9.2	6.6–12.5	0.879
35–39	361	17	4.7	2.8–7.4	0.031
40–44	343	16	4.7	2.7–7.5	0.032
45–50	468	23	4.9	3.1–7.3	0.028
Total	2293	158	6.9	5.9–8.0	

[a] Logistic regression analysis with age groups as categorical variable.



Fig. 1. Age-specific prevalence of high-risk HPV in women with normal cytology, 10-year intervals.